^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG:

    NBE-002

    i
    Other names: NBE-002, PNU-159682-anti-ROR1 antibody drug conjugate, huXBR1-402-G5-PNU, BI 3702025
    Company:
    Boehringer Ingelheim, Sotio
    Drug class:
    DNA replication inhibitor, ROR1-targeted antibody-drug conjugate
    Related drugs:
    7ms
    The antibody-drug conjugate targeting ROR1, NBE-002, is active in high-grade serous ovarian cancer preclinical models. (PubMed, Ther Adv Med Oncol)
    This study explored the anti-cancer effects of NBE-002 alone and in combination with standard HGSOC therapies, carboplatin, paclitaxel and olaparib. The ROR1-targeting ADC, NBE-002, has therapeutic potential in HGSOC, with single agent activity observed both in vitro and in vivo. Broader clinical applications were evident when NBE-002 was combined with carboplatin or olaparib.
    Preclinical • Journal • BRCA Biomarker • PARP Biomarker
    |
    BRCA2 (Breast cancer 2, early onset) • HRD (Homologous Recombination Deficiency) • ROR1 (Receptor Tyrosine Kinase Like Orphan Receptor 1)
    |
    HRD
    |
    Lynparza (olaparib) • carboplatin • paclitaxel • NBE-002
    over4years
    [VIRTUAL] NBE-002: A novel anthracycline-based antibody-drug conjugate (ADC) targeting ROR1 for the treatment of advanced solid tumors—A phase 1/2 clinical trial. (ASCO 2021)
    Ph 1 dose escalation was initiated on 17 JULY 2020 and is still recruiting in the US . Ph 2 is planned to be initiated in 2022.
    Clinical • P1/2 data
    |
    CD8 (cluster of differentiation 8) • ROR1 (Receptor Tyrosine Kinase Like Orphan Receptor 1)
    |
    ROR1 expression
    |
    NBE-002